What the Ebola Case Means for Mutual Fund Investors
Continue to site >
Trending ETFs

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

What the Ebola Case Means for Mutual Fund Investors

Shauna O'Brien

|

Business news with 3-d bar charts on top
After killing more than 3,000 people in West Africa, Ebola has been reported for the first time in the U.S. While the disease has the U.S. frightened of an outbreak, it has also gained attention from investors.

What Ebola Means for Investors

The disease is one of the most deadly as there is currently no cure and the infection can kill within days.

Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”

The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.

The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).

Mutual Funds to Watch

There are several companies that could benefit from drugs made for the Ebola virus. Below are mutual funds with exposure to key drug makers.
Ticker Mutual Fund Exposure % of Shares Owned
FBDIX Franklin Biotechnology Discovery A Tekmira Pharmaceuticals (TKMR) 3.15%
SHSAX BlackRock Health Sciences Opps Inv A Tekmira Pharmaceuticals (TKMR) 1.53%
FBIOX Fidelity Select Biotechnology Portfolio NewLink Genetics Corp (NLNK) 5.93%

The Bottom Line

While the Ebola case has the potential to be devastating in the U.S., it may also present an opportunity for investors to see some upside in the biotech and pharmaceutical industries.

There are several mutual funds that offer specific exposure to these industries including the funds listed above.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Business news with 3-d bar charts on top

What the Ebola Case Means for Mutual Fund Investors

Shauna O'Brien

|

After killing more than 3,000 people in West Africa, Ebola has been reported for the first time in the U.S. While the disease has the U.S. frightened of an outbreak, it has also gained attention from investors.

What Ebola Means for Investors

The disease is one of the most deadly as there is currently no cure and the infection can kill within days.

Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”

The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.

The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).

Mutual Funds to Watch

There are several companies that could benefit from drugs made for the Ebola virus. Below are mutual funds with exposure to key drug makers.
Ticker Mutual Fund Exposure % of Shares Owned
FBDIX Franklin Biotechnology Discovery A Tekmira Pharmaceuticals (TKMR) 3.15%
SHSAX BlackRock Health Sciences Opps Inv A Tekmira Pharmaceuticals (TKMR) 1.53%
FBIOX Fidelity Select Biotechnology Portfolio NewLink Genetics Corp (NLNK) 5.93%

The Bottom Line

While the Ebola case has the potential to be devastating in the U.S., it may also present an opportunity for investors to see some upside in the biotech and pharmaceutical industries.

There are several mutual funds that offer specific exposure to these industries including the funds listed above.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.